Overview

We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put NantKwest, Inc.'s financial performance into perspective.
Recent NewsMore >>
DateTitle 
05/17/16NantKwest Provides Update on Clinical Programs at Bank of America Healthcare Conference Multiple Immunotherapy Combinations Announced as Part of Cancer Moonshot 2020 Initiative
CULVER CITY, Calif.--(BUSINESS WIRE)--May 17, 2016-- NantKwest Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases, provided an update today on the company’s aNK, haNK and taNK clinical programs in a presentation at the Bank of America Merrill Lynch 2016 Health Care ... 
Printer Friendly Version
05/09/16DR. PATRICK SOON-SHIONG TO GIVE KEYNOTE ADDRESS AND NANTKWEST TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH 2016 HEALTH CARE CONFERENCE
Culver City, May 6, 2016 -- NantKwest, Inc (Nasdaq:NK), today announced that Dr. Patrick Soon-Shiong, NantKwest's Chairman and CEO will be giving the Keynote address and NantKwest will be presenting at the Bank of America Merrill Lynch 2016 Health Care Conference in Las Vegas, Nevada on Tuesday, May 10, 2016.   NantKwest's presentation will be at 1:00 pm PT and will include an update and business overview by company management. The webcast will be accessible on the Investor Re... 
Printer Friendly Version
04/15/16NantKwest to Present Data on the First Next Generation GMP-Grade NK Cell Line for Combination Immunotherapy with Rituximab, Trastuzumab, and Daratumumab at Upcoming AACR Cancer Conference
Positive Preclinical Data Of The First “Off The Shelf,” GMP-Grade, IL-2-Independent NK Cell Line Expressing The High-Affinity Fc-Receptor To Augment Antibody Therapeutics CULVER CITY, Calif. – April 15, 2016 - NantKwest Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases, today annou... 
Printer Friendly Version
04/05/16NantBioScience and NantKwest Partner with the National Cancer Institute to Further Develop Recombinant NK Cells and Monoclonal Antibodies as Monotherapies and Combination Cancer Immunotherapies
Culver City, California, April 5, 2016—NantBioScience, Inc., is a biopharmaceutical company focused on the discovery of innovative treatments by developing molecularly targeted drugs, based on the molecular profile of the patient’s tumor, independent of the cancer’s anatomical type. NantKwest, Inc. (Nasdaq: NK), an affiliate of NantBioScience, is a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using natural killer cells to treat cancer, infec... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Past EventsMore >>
DateTitle
05/10/16 1:00 p.m. PT
Nantkwest Inc at Bank of America Merrill Lynch 2016 Health Care Conference
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Nantkwest Inc posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed.